PLA2G12A
Group XIIA secretory phospholipase A2
Also known as: PG12A_HUMAN, PLA2G12
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q9BZM1
- Gene
- PLA2G12A
- Ensembl
- ENSG00000123739
- Chromosome
- 4
- Canonical length
- 189 aa
- Protein class
- Enzymes, Metabolic proteins, Predicted secreted proteins, RAS pathway related proteins
- Secretome location
- Secreted to blood
OverviewNCBI Gene
Secreted phospholipase A2 (sPLA2) enzymes liberate arachidonic acid from phospholipids for production of eicosanoids and exert a variety of physiologic and pathologic effects. Group XII sPLA2s, such as PLA2G12A, have relatively low specific activity and are structurally and functionally distinct from other sPLA2s (Gelb et al., 2000 [PubMed 11031251]).[supplied by OMIM, Mar 2008]
Canonical amino-acid sequenceUniProt
189 residues, UniProt reviewed canonical sequence.
>Q9BZM1|PLA2G12A
1 MALLSRPALT LLLLLMAAVV RCQEQAQTTD WRATLKTIRN GVHKIDTYLN AALDLLGGED
61 GLCQYKCSDG SKPFPRYGYK PSPPNGCGSP LFGVHLNIGI PSLTKCCNQH DRCYETCGKS
121 KNDCDEEFQY CLSKICRDVQ KTLGLTQHVQ ACETTVELLF DSVIHLGCKP YLDSQRAACR
181 CHYEEKTDLLocalizationUniProt · AlphaFold · HPA
Whether an antibody against PLA2G12A can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.4
- Highest tissue expression
- 35 nTPM
Expression across tissuesHPA
Tissue
- pancreas: 35 nTPM
- parathyroid gland: 22 nTPM
- skeletal muscle: 22 nTPM
- tongue: 20 nTPM
- spinal cord: 19 nTPM
- liver: 19 nTPM
Single-cell type
- platelets: 500 nCPM
- megakaryocytes: 105 nCPM
- parietal cells: 83 nCPM
- hepatocytes: 80 nCPM
- granulosa cells: 67 nCPM
- choroid plexus epithelial cells: 66 nCPM
Immune cell
- total PBMC: 12 nTPM
- naive CD4 T-cell: 8.7 nTPM
- T-reg: 8.3 nTPM
- myeloid DC: 8.2 nTPM
- naive CD8 T-cell: 8 nTPM
- memory CD4 T-cell: 7.8 nTPM
Brain region
- white matter: 28 nTPM
- midbrain: 28 nTPM
- spinal cord: 28 nTPM
- medulla oblongata: 27 nTPM
- thalamus: 25 nTPM
- cerebellum: 24 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.44
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.2
- DepMap mean gene effect
- -0.18
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads PLA2G12A as an antibody target. Whether an autoantibody or antibody against PLA2G12A could matter depends on whether native PLA2G12A is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
PLA2G12A is annotated as secreted, so native PLA2G12A circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label PLA2G12A as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...